Document is current
Any future updates will be listed below
-
Authors
Shalabi, Haneen
Gust, Juliane
Taraseviciute, Agne
Wolters, Pamela L.
Leahy, Allison B.
Sandi, Carlos
Laetsch, Theodore W. https://orcid.org/0000-0002-8497-3138
Wiener, Lori https://orcid.org/0000-0002-9573-8870
Gardner, Rebecca A.
Nussenblatt, Veronique
Hill, Joshua A.
Curran, Kevin J.
Olson, Timothy S.
Annesley, Colleen
Wang, Hao-Wei https://orcid.org/0000-0002-5408-9253
Khan, Javed https://orcid.org/0000-0002-5858-0488
Pasquini, Marcelo C.
Duncan, Christine N.
Grupp, Stephan A.
Pulsipher, Michael A.
Shah, Nirali N. https://orcid.org/0000-0002-8474-9080
- License Information
-
More Information
Article History
Accepted: 20 November 2020
First Online: 25 January 2021
Competing interests
: J.G. is a consultant for Johnson & Johnson. T.W.L. has consulted for Bayer, Cellectis and Novartis; and his institution has research funding from Bayer, Novartis and Pfizer. R.A.G. has received honoraria from Novartis. J.A.H. has consulted for Allogene Therapeutics. K.J.C. has received research support from Juno Therapeutics and Novartis and has consulted and participated in advisory boards or educational seminars for Juno Therapeutics, Mesoblast and Novartis. M.C.P. has received research support from BMS, Kite and Novartis, and has been a consultant for Amgen and BMS. S.A.G. receives research support from Kite, Novartis and Servier; is a consultant for CBMG, GSK, Humanigen, Janssen/Johnson & Johnson, Novartis and Roche; is a study steering committee or scientific advisory board member for Adaptimmune, Allogene, Cellectis, Jazz, Juno, Novartis, TCR2 and Vertex/CRISPR; and has a patent (WO 2014011984 A1) that is managed according to the University of Pennsylvania patent policy. M.A.P. has received fees from Novartis, grants and personal fees from Miltenyi, grants from Adaptive, and personal fees from Mesoblast. The remaining authors declare no competing interests.
